Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 13/20 | 0.47 |
| ▸ | CTSS | P25774 | 10/20 | 0.47 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | CTSV | O60911 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4766721 | 0.89 | CTSK (0.46) | CTSKTAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL4766723 | 0.89 | CTSK (0.46) | CTSKTAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL6591711 | 0.89 | CTSK (0.46) | CTSKTAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL6591709 | 0.89 | CTSK (0.46) | CTSKTAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL4762139 | 0.89 | CTSK (0.46) | CTSKTAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL4823328 | 0.89 | CTSK (0.46) | CTSKTAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL4768797 | 0.88 | CTSK (0.45) | CTSKTAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL4821292 | 0.88 | CTSK (0.56) | CTSKCTSLCTSSCTSBCTSV | |
| SCHEMBL4763041 | 0.88 | CTSK (0.47) | CTSKTAS1R3TAS1R1CTSLCTSS | |
| SCHEMBL4768953 | 0.88 | CTSK (0.45) | CTSKTAS1R3TAS1R1CTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION | 2005-11-17 | — | — | US | claimed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256104-A1 | substituted 1,1,4-1l6-trioxo[1,2]thiazepan-4-ylamide-derived protease inhibitors which inhibit the likes of cathepsin K; treating osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | CTSK, CTSZ, CTSE | CTSK 1/4885TAS1R3 1703/4885TAS1R1 1423/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885TAS1R3 2506/4885TAS1R1 3023/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | CTSK 1/4885TAS1R3 2506/4885TAS1R1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.